Last reviewed · How we verify
Non-small cell lung cancer, positive for epidermal growth factor receptor expression
Approved treatments
- Iressa · David Adelstein
- Gilotrif · Boehringer Ingelheim
Gilotrif works by blocking the epidermal growth factor receptor, a protein that helps cancer cells grow. - Tagrisso · Suzhou Genhouse Bio Co., Ltd.
- dacomitinib hydrate · Pfizer Inc.
The usual adult starting dosage for oral use is 45mg of dacomitinib hydrate once daily. The dose sho - Vizimpro · Pfizer Inc.
Irreversible pan-HER kinase inhibitor targeting EGFR, HER2, HER4, and EGFR-activating mutations. - Iressa · Pfizer Inc.
Iressa blocks the epidermal growth factor receptor (EGFR) signaling pathway, preventing cancer cell growth and proliferation. - Vizimpro · Pfizer
Vizimpro works by blocking the EGFR tyrosine kinase, a protein that helps cancer cells grow and survive. - Gilotrif · Seoul St. Mary's Hospital
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Non-small cell lung cancer, positive for epidermal growth factor receptor expression patent landscape — cliff calendar, originator estates, attackable patents
- Non-small cell lung cancer, positive for epidermal growth factor receptor expression treatment landscape brief
- Non-small cell lung cancer, positive for epidermal growth factor receptor expression treatment updates RSS
Frequently asked questions about Non-small cell lung cancer, positive for epidermal growth factor receptor expression
What drugs treat Non-small cell lung cancer, positive for epidermal growth factor receptor expression?
Tracked treatments include Iressa, Gilotrif, Tagrisso, dacomitinib hydrate, Vizimpro.
What is the treatment for Non-small cell lung cancer, positive for epidermal growth factor receptor expression?
Standard treatment for Non-small cell lung cancer, positive for epidermal growth factor receptor expression includes Iressa, Gilotrif, Tagrisso, dacomitinib hydrate, Vizimpro. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Non-small cell lung cancer, positive for epidermal growth factor receptor expression patent cliff · Non-small cell lung cancer, positive for epidermal growth factor receptor expression CI report
- Treatment: Iressa · David Adelstein
- Treatment: Gilotrif · Boehringer Ingelheim
- Treatment: Tagrisso · Suzhou Genhouse Bio Co., Ltd.
- Treatment: dacomitinib hydrate · Pfizer Inc.
- Treatment: Vizimpro · Pfizer Inc.
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing